Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
Date:9/17/2009

cus of the company and aligning our clinical drug programs, we signed a very important partnership for the company in our fourth quarter with Servier, the largest private French Biotech firm, and received immediately $11.0 million with an additional $4.0 million in future research payments and $2.0 million in future product purchases. Together with these payments over the next two years and our most recent rights offering of $28.8 million and the equity raised during this spring of $1.4 million, the new team at Pharmacyclics is responsible for generating more than $45.0 million in new capital." said Robert W. Duggan, Chairman of the Board and Chief Executive Officer. "We now have the funds to progress our four clinical programs in a meaningful way and continue to advance these novel product candidates."

Recent and Upcoming Milestones and Program Updates

  • Raised approximately net $28.0 million in a July 2009 rights offering. This financing gave all existing share holders the opportunity to participate in the company's fund raising. After retiring its loan obligation the rights offering provided net approximately $21.6 million in cash.
  • Partnered PCI-24781, Pharmacyclics' oral HDAC inhibitor, with Servier, granting exclusive licensing for all ex-U.S. markets and providing the company with a royalty on future sales, plus $11.0 million in up front payments, $4.0 million in research payments during the next 24 months as well as potential milestone payments of $24.5 million. PCI -24781 is currently in a U.S. Phase I/II study in patients with Non-Hodgkin's lymphoma and continues to have a class leading safety profile. PCI-24781 was well tolerated in heavily pretreated patients with relapsed/refractory Non-Hodgkin's lymphoma, with promising clinical responses in the Phase I portion of the trial. Data will be presented at the December 2009 ASH meeting in New Orleans. Servier, Pharmacyclics' European partner, is in t
    '/>"/>

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Pharmacyclics Sets Record Date for Rights Offering
2. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
4. Pharmacyclics Receives Nasdaq Notification
5. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
6. Pharmacyclics Reports Third Quarter 2008 Financial Results
7. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
10. J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance
11. Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... SAN JOSE, Calif. (PRWEB) November 22, 2014 ... related security applications was announced today which safely ... body using high frequency radio waves. Developed by ... nude images and hosts broad applications in other ... in addition to security. , Using high frequency ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Greenfield Naturals” ... Tech Report , which features the latest and ... technology expert and reporter for NewsWatch, conducted the product ... improve the flavor of your water. , From pollution ... It’s important that everything is done to remove these ...
(Date:11/22/2014)... OH (PRWEB) November 22, 2014 A Xarelto ... York woman who is seeking $10 million in damages from ... thinner . According to the lawsuit, the woman began using ... The woman alleges in her lawsuit she suffered life-threatening bleeding ... permanent personal injuries, pain, suffering and emotional distress. The lawsuit ...
(Date:11/22/2014)... 21, 2014 (HealthDay News) -- Many young people consider ... a new study finds fumes from the water pipes ... to an increased risk for leukemia in prior research, ... the journal Cancer Epidemiology, Biomarkers & Prevention . ... smoking is not a safe alternative to smoking other ...
(Date:11/22/2014)... By Steven Reinberg ... -- Stroke outcomes are better when patients are treated in ... and clot-busting drugs, German researchers report. The sooner patients ... the better the outcome after a stroke, the researchers noted. ... within the first hour after stroke symptoms start, the researchers ...
Breaking Medicine News(10 mins):Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... Group,Inc. (Amex: QGP ), a Wellington, Florida ... President & Chief Executive Officer,will be presenting at ... 2008. Mr. Guillama will be joined by Pete,Martinez, ... Officer,and Ron Smith, Senior Vice President Corporate Development. ...
... Calif., Nov. 4 CorVel Corporation,(Nasdaq: CRVL ) reported ... 2008, compared to $0.40 in the same quarter of the ... were $0.75 per,share compared to the same period in the ... quarterly revenues of $78 million, up from prior,year quarterly revenues ...
... France, November 4 PCAS has,launched its new ... This new site provides detailed information on ... speciality fine chemicals., It focuses on R&D ... technologies in detail., What is more, the ...
... medical equipment supplier notes while sales soar, more customers are trying ... ... Stratford, Connecticut (PRWEB) November 4, 2008 - Medisave ( www.medisave.net ), ... operations in UK, USA, Europe, New Zealand and Australia, today announced ...
... by National Institute of Allergy and Infectious Diseases (NIAID) ... evidence associating seizures with areas of brain tissue swelling ... called perilesional edemas, form around dead, calcified cysts that ... lodge in the brain. The illness caused by ...
... SOUTH FLORIDA NOVEMBER 20, 2008, JUPITER, Fla., Nov. 3 ... in the Sunshine State to promote,National Smoke Out Day, November 20, ... kick the smoking habit., -- MISS AMERICA 2008 ... NEWSPAPER INTERVIEWS FROM NOVEMBER 15-17 TO PROMOTE SAVING LIVES, ...
Cached Medicine News:Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3Health News:CorVel Announces Second Quarter Revenues and Earnings 2Health News:CorVel Announces Second Quarter Revenues and Earnings 3Health News:CorVel Announces Second Quarter Revenues and Earnings 4Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 2Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 3
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
(Date:11/21/2014)... , Nov. 21, 2014  Tandem Diabetes ... ), a medical device company and manufacturer of ... a partnership with Tidepool, a non-profit dedicated to ... source software platform that increases diabetes data accessibility. ... Platform, which is currently under development, to download ...
(Date:11/21/2014)... Fla. , Nov. 21, 2014   Rock ... announced that the Company is scheduled to present at ... San Francisco, CA on January 12-14, 2015. ... Chairman and CEO of Rock Creek Pharmaceuticals, will present ... molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4
... Inc. (NASDAQ: OPTR ) will report fourth ... provide a business overview, including DIFICID® sales, commercialization and ... 7th.  The Company will host a conference call the ... Pacific Time). (Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ...
... MISSISSAUGA, Ontario, Feb. 27, 2012 Fourth Quarter 2011 ... 34% over the prior year Pro forma organic growth, ... 2011 Fourth Quarter GAAP EPS $0.18; Cash EPS $0.94 2011 ... million   Full Year 2011 ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results 2Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 2Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 3Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 4Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 5Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 6Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 7Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 8Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 9Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 10Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 11Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 12Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 13Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 14Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 15Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 16Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 17Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 18Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 19
Townsend is a endocervical stainless-steel curette with round tapered tip....
...
...
...
Medicine Products: